$0.97
5.15% day before yesterday
Nasdaq, Jun 06, 10:00 pm CET
ISIN
IL0011319527
Symbol
ENLV

Enlivex Therapeutics Ltd Stock price

$0.97
-0.13 12.05% 1M
-0.28 22.61% 6M
-0.20 17.32% YTD
-0.41 29.90% 1Y
-4.35 81.82% 5Y
-236.23 99.59% 10Y
-335.03 99.71% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.05 5.15%
ISIN
IL0011319527
Symbol
ENLV
Sector

Key metrics

Market capitalization $23.07m
Enterprise Value $2.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.12
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-15.09m
Free Cash Flow (TTM) Free Cash Flow $-13.21m
Cash position $20.55m
EPS (TTM) EPS $-0.60
P/E forward negative
Short interest 0.53%
Show more

Is Enlivex Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Enlivex Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Enlivex Therapeutics Ltd forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Enlivex Therapeutics Ltd forecast:

Buy
100%

Financial data from Enlivex Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.77 4.77
15% 15%
-
- Research and Development Expense 10 10
38% 38%
-
-15 -15
32% 32%
-
- Depreciation and Amortization 0.45 0.45
44% 44%
-
EBIT (Operating Income) EBIT -15 -15
32% 32%
-
Net Profit -14 -14
45% 45%
-

In millions USD.

Don't miss a Thing! We will send you all news about Enlivex Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enlivex Therapeutics Ltd Stock News

Neutral
GlobeNewsWire
19 days ago
Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company has been selected to present at the upcoming Israeli BioMed 2025 Conf...
Neutral
GlobeNewsWire
about 2 months ago
Presentations to underscore AllocetraTM's novel mechanism targeting immune imbalance in joint disease Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI)...
Neutral
GlobeNewsWire
about 2 months ago
Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis. Ov...
More Enlivex Therapeutics Ltd News

Company Profile

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Head office Israel
CEO Dr. Hershkovitz
Employees 71
Founded 2012
Website www.enlivex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today